Merck Cozaar has 2.5% share of ACE inhibitor market -- Scott-Levin data.
Executive Summary
MERCK COZAAR HAS 2.5% SHARE OF ACE INHIBITOR MARKET as of July 14, according to Scott-Levin Associates' Rx Watch. The angiotensin II inhibitor losartan held a 1.4% share of new prescriptions for the month of June, with 22,000 scripts, Scott-Levin reported. The losartan/hydrochlorothiazide combination product Hyzaar held a 1.6% share of the ACE inhibitor/diuretic combo market in June, with 3,000 scripts, Scott-Levin said.